4.5 Article

PLC/CAMK IV-NF-κB involved in the receptor for advanced glycation end products mediated signaling pathway in human endothelial cells

Journal

MOLECULAR AND CELLULAR ENDOCRINOLOGY
Volume 320, Issue 1-2, Pages 111-117

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/j.mce.2010.01.036

Keywords

Diabetic vascular complications; Advanced glycation end products; Ca(2+) signaling pathway; NF-kappa B; Inflammation

Funding

  1. Natural Science Foundation of Fujian Province, China [C0720017]

Ask authors/readers for more resources

Advanced glycation end products (AGEs) and their interaction with the receptor for advanced glycation end products (RAGE) play an important role in diabetic vascular complications. The current study demonstrated that AGEs significantly increased RAGE expression and the release of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) in human umbilical vein endothelial cell-derived line ECV304 cells. RAGE antisense RNA partially inhibited the expression of TNF-alpha and IL-6 induced by AGEs. Oligonucleotide microarray was used to identify the genes that respond to RAGE activation. Phospholipase C beta 1 (PLC beta 1), phospholipase C beta 4 (PLC beta 4) and calcium/calmodulin-dependent protein kinase IV (CAMK IV) which associated with Ca(2+) signaling were upregulated. The rise of intracellular calcium and the NF-kappa B promoter activity induced by AGEs were suppressed by RAGE antisense RNA. PLC inhibitor U73122 and dominant negative CAMK IV, respectively. These findings suggest that PLC/CAMK IV-NF-kappa B is involved in RAGE mediated signaling pathway in human endothelial cells. (C) 2010 Elsevier Ireland Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available